Publicaciones en colaboración con investigadores/as de Instituto Cajal (23)

2024

  1. The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls

    EMBO Molecular Medicine

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process

    Gut Microbes, Vol. 12, Núm. 1

  2. Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure

    Neuropsychopharmacology, Vol. 45, Núm. 5, pp. 877-886

  3. Synthesis, antioxidant properties and neuroprotection of α-phenyl-tert-butylnitrone derived HomoBisNitrones in in vitro and in vivo ischemia models

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. E3 ubiquitin ligases LNX1 and LNX2 are major regulators of the presynaptic glycine transporter GlyT2

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Development of a Fluorescent Bodipy Probe for Visualization of the Serotonin 5-HT 1A Receptor in Native Cells of the Immune System

    Bioconjugate Chemistry, Vol. 29, Núm. 6, pp. 2021-2027

  2. 2-AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs

    GLIA, Vol. 66, Núm. 7, pp. 1447-1463

2017

  1. 2-arachidonoylglycerol reduces proteoglycans and enhances remyelination in a progressive model of demyelination

    Journal of Neuroscience, Vol. 37, Núm. 35, pp. 8385-8398

2015

  1. A Basal Tone of 2-Arachidonoylglycerol Contributes to Early Oligodendrocyte Progenitor Proliferation by Activating Phosphatidylinositol 3-Kinase (PI3K)/AKT and the Mammalian Target of Rapamycin (MTOR) Pathways

    Journal of Neuroimmune Pharmacology, Vol. 10, Núm. 2, pp. 309-317

  2. Endocannabinoids drive the acquisition of an alternative phenotype in microglia

    Brain, Behavior, and Immunity, Vol. 49, pp. 233-245

2014

  1. A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis

    Angewandte Chemie - International Edition, Vol. 53, Núm. 50, pp. 13765-13770

2012

  1. Chemical probes for the recognition of cannabinoid receptors in native systems

    Angewandte Chemie - International Edition, Vol. 51, Núm. 28, pp. 6896-6899

2011

  1. Prospects for cannabinoid therapies in basal ganglia disorders

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1365-1378

2006

  1. El sistema cannabinoide en situaciones de neuroinflamación: Perspectivas terapéuticas en la esclerosis múltiple

    Revista de Neurologia, Vol. 43, Núm. 9, pp. 541-548

2005

  1. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis

    FASEB Journal, Vol. 19, Núm. 10, pp. 1338-1340

  2. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures

    GLIA, Vol. 52, Núm. 2, pp. 163-168

  3. Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation

    Journal of Neuroscience, Vol. 25, Núm. 8, pp. 1904-1913

  4. The role of cannabinoids in preventing the neurodegenerative process occurring in Alzheimer's disease

    Drugs of the Future, Vol. 30, Núm. 8, pp. 807-814

2002

  1. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway

    Journal of Biological Chemistry, Vol. 277, Núm. 39, pp. 36527-36533